Press Release Archive

Johnson & Johnson to Participate in the 40^th Annual J.P. Morgan Healthcare Conference

Johnson & Johnson to Participate in the 40^th Annual J.P. Morgan Healthcare Conference

Innovation December 05, 2021

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

Preliminary Phase 2 study and a sub-study demonstrate value of mix-and-match approach; Johnson & Johnson booster increased neutralizing and binding antibodies, similar to boosting with BNT162b2, and showed strong increase in T-cell responses

Innovation December 03, 2021

Latest Phase 3 Data for First-in-Class TREMFYA^® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)

Latest Phase 3 Data for First-in-Class TREMFYA^® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)

The COSMOS study met its primary endpoint, with a significantly higher proportion of TREMFYA-treated patients (44.4 percent) versus placebo-treated patients (19.8 percent) achieving ACR20 response at week 24; the TREMFYA treatment effect in these TNFi-IR patients was seen by week four

Response rates continued to improve at one year (week 48) with 57.7 percent of TREMFYA patients achieving ACR20 with a similar safety profile (week 56)

TREMFYA is the first and only selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for moderate to severe plaque psoriasis and active psoriatic arthritis irrespective of prior TNFi exposure

Innovation November 30, 2021

Janssen Seeks Approval of IMBRUVICA^®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)

Janssen Seeks Approval of IMBRUVICA^®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)

Application based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the safety and efficacy of an all-oral fixed-duration ibrutinib plus venetoclax combination regimen in adult patients with previously untreated CLL (1) (2)

Media Statement November 30, 2021

Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

Our Company November 30, 2021

Johnson & Johnson announces significant progress towards its climate goals – 100% renewable electricity for all sites in the United States, Canada and Europe by 2023

Johnson & Johnson announces significant progress towards its climate goals – 100% renewable electricity for all sites in the United States, Canada and Europe by 2023

Media Statement November 29, 2021

Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant

Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant

Innovation November 24, 2021

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older

Vaccine demonstrates protection against COVID-19 related hospitalization and death, and across different variants

Media Statement November 22, 2021

Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower Income Countries Through COVAX

Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower Income Countries Through COVAX

Company Welcomes Leadership Shown by the European Commission and EU Member States, plus Norway and Iceland to Help Advance Equitable Access to Our Vaccine

Innovation November 17, 2021

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA^® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA^® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease

The Phase 3 GALAXI 2 and 3 studies are continuing to enroll

Internet Explorer is no longer supported by this website.

Topic